Zura Bio Limited announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company, on March 20, 2023.
Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp Read More »
Selecta Biosciences, Inc. and Sobi®, announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials to determine safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout.
The 2023 Annual Meeting of American Academy of Dermatology Association was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States.
Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.
Cytovation appoints Iman Barilero as Chief Development Officer Read More »
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that in accordance with the Mongolian law on the prevention of novel coronavirus outbreak, the Company was granted an Emergency Use Authorization for its two-component recombinant COVID-19 vaccine ReCOV by Order No. A106 of the Minister of Public Health of Mongolia and a resolution of the
Scorpius BioManufacturing, a Texas-based biologics contract research and contract development & manufacturing organization, announced the appointment of Gary Welch as Interim President.
Scorpius BioManufacturing Announces the Appointment of Gary Welch as Interim President Read More »
Oxford Nanopore Technologies plc and PathoQuest announce the agreement of a MOU for a collaboration to commercialise a transformational Integration Site Analysis test to better meet the evolving needs of the biopharmaceutical industry and the advancement of biological therapeutics.
Mainz Biomed NV announced that Bill Caragol, the Company’s CFO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 22-23, 2023.
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23 Read More »
The European Commission has approved Dupixent® in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.
Nicox SA, an international ophthalmology company, announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress which will be held from June 28 to July 1st, 2023 in Rome, Italy.
